Functionalized nanosponges for controlled antibacterial and antihypocalcemic actions.
The aim of the present work was to develop lysozyme impregnated surface-active nanosponges to maintain its conformational stability and break bacterial cell walls by catalyzing the hydrolysis of 1,4-β-linkages between N-acetyl-d-glucosamine and N-acetylmuramic acid residues present in peptidoglycan layer surrounding the bacterial cell membrane, and for controlling the release of calcium in hypocalcemia condition. Different carbonyl diimidazole cross-linked β-cyclodextrin nanosponges with and without CaCO3and CMC were prepared by polymer condensation method. The surface-active nanosponges were impregnated by lysozyme due to their ability to adsorb protein. Lysozyme impregnated nanosponges had a monomodal particle size distribution of 347.46±3.07 to 550.34±5.23nm, with a narrow distribution. The zeta potentials were sufficiently increased upon lysozyme impregnation, suggesting stable formulations by preventing aggregation. The in vitro release studies showed controlled release of lysozyme and calcium over a period of 24h. FTIR studies confirmed the impregnation of lysozyme on nanosponges and encapsulation of calcium in nanosponges. Lysozyme formulation showed promising conformational stability by DSC. It can be concluded that the stable nanosponges formulation is a promising carrier for antibacterial protein and preventing depletion of calcium in antibiotic associated hypocalcemic condition.
Department of Science and Technology of Pharmaceutics, University of Torino, Italy; Faculty of Pharmaceutical Sciences, Jodhpur National University, Jodhpur, Rajasthan, India. Electronic address: kirandeshmukh8@gmail.com.
Kiran
K
Deshmukh
Bhupal Nobles' College of Pharmacy, Udaipur, Rajasthan, India.
Yuveraj Singh
YS
Tanwar
Faculty of Pharmaceutical Sciences, Jodhpur National University, Jodhpur, Rajasthan, India.
Shailendra
S
Sharma
SPP-School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai, India.
Pravin
P
Shende
Department of Science and Technology of Pharmaceutics, University of Torino, Italy.
Roberta
R
Cavalli
D000327:Adsorption; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001681:Biological Assay; D002118:Calcium / Q000378:metabolism; D002152:Calorimetry, Differential Scanning; D003692:Delayed-Action Preparations; D006996:Hypocalcemia / Q000188:drug therapy*; D008297:Male; D009113:Muramidase / Q000378:metabolism; D053758:Nanoparticles / Q000627:therapeutic use* / Q000648:ultrastructure; D010316:Particle Size; D017208:Rats, Wistar; D017550:Spectroscopy, Fourier Transform Infrared; D055672:Static Electricity
D000900:Anti-Bacterial Agents; D003692:Delayed-Action Preparations; D009113:Muramidase; D002118:Calcium
Antibacterial action; Hypocalcemic action; Nanosponges; β-Cyclodextrin